LIPID OPTIMIZATION AMONG PATIENTS WITH PERIPHERAL ARTERY DISEASE FOLLOWING REVASCULARIZATION IN A SINGLE-CENTER COHORT
Therapeutic Area: Peripheral Artery Disease Background: Lipid management is a cornerstone of peripheral artery disease (PAD) treatment to reduce major adverse cardiac events. The 2018 ACC/AHA cholesterol guidelines recommended statins, ezetimibe, and/or PCSK9 inhibitors in selected patients to reach...
Saved in:
Main Author: | Franck H. Azobou Tonleu, MD (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2024-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
USE OF GLP-1 RECEPTOR AGONISTS AND/OR SGLT-2 INHIBITORS AMONG PATIENTS WITH PERIPHERAL ARTERY DISEASE BEFORE AND AFTER REVASCULARIZATION IN A SINGLE-CENTER COHORT
by: Franck H. Azobou Tonleu, MD
Published: (2024) -
Comparison of rivaroxaban-based dual antithrombotic and antiplatelet therapies for symptomatic patients with lower-extremity peripheral artery disease post-revascularization: a retrospective cohort study
by: Ye Ji, et al.
Published: (2023) -
Long term outcomes of surgical revascularization for isolated left main coronary artery stenosis: a single-center surveillance study
by: Yalçın Velibey, et al.
Published: (2015) -
Efficacy and Safety of Rivaroxaban Compared with Other Therapies Used in Patients with Peripheral Artery Disease Undergoing Peripheral Revascularization: A Systematic Literature Review and Network Meta-Analysis
by: Rupert Bauersachs, et al.
Published: (2021) -
Mono or Dual Antiplatelet Therapy for Treating Patients with Peripheral Artery Disease after Lower Extremity Revascularization: A Systematic Review and Meta-Analysis
by: Shang-Yu Tsai, et al.
Published: (2022)